Functional improvement of dystrophic muscle by myostatin blockade
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Mice and cattle with mutations in the myostatin (GDF8) gene show a marked increase in body weight and muscle mass, indicating that this new member of the TGF-beta superfamily is a negative regulator of skeletal muscle growth. Inhibition of the myostatin gene product is predicted to increase muscle mass and improve the disease phenotype in a variety of primary and secondary myopathies. We tested the ability of inhibition of myostatin in vivo to ameliorate the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies for three months resulted in an increase in body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration and concentrations of serum creatine kinase. The functional improvement of dystrophic muscle by myostatin blockade provides a novel, pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD, and circumvents the major problems associated with conventional gene therapy in these disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The interest in myostatin was generated by recent studies where antibodies for myostatin were created and administered to adult rodents, which resulted in an increase in body mass, muscle mass, muscle size, and strength [11,12].”
From Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males (2006) · cites this paper as [12]
Citations
Cites
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
TEXTBOOK OF MEDICAL PHYSIOLOGY
GUYTON, A. C. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196701000-00031 · Cited by 2,837
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802 · cited 1×
“In comparison with conventional transgenic, cell and gene therapy approache”
BackgroundX chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Alterations in Smad 2 and 3 phosphorylation would be predicted to regulate the formation of Smad complexes, their nuclear translocation and transcriptional regulation of genes associated with commitment of muscle progenitor”
BackgroundA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526 · cited 1×
“The regimen did not completely reverse dystrophic changes; physiological parameters evaluated by ex vivo tests, such as susceptibility to damage by lengthening contraction”
BackgroundAhima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citation
Research works printed but not linked: 2
- Jalenak, M. et al. Transcriptional changes arising from in vivo inhibition of myostatin. J. Neurol. Sci. 199 (suppl)., S83 (2002)
- Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw-Hill, New York, 1994)
Cited by
Items 601–700 of 853
Cyclo His‐Pro Attenuates Muscle Degeneration in Murine Myopathy Models
Masi, A. D., Zanou, N., Strotjohann, K., Lee, D., de Lima, T. I., Li, X., Jeon, J., Place, N., Jung, H., & Auwerx, J. H. (2024) · Advanced Science · doi:10.1002/advs.202305927 · Cited by 9
Diagnostic and predictive abilities of myokines in patients with heart failure
Berezin, O. O., Berezina, T. A., Hoppe, U. C., Lichtenauer, M., & Berezin, A. Е. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.12.021 · Cited by 9
Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients
Mackels, L., Mariot, V., Buscemi, L., Servais, L., & Dumonceaux, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168763 · Cited by 10
“…mouse models [45] confirmed the increase in muscle mass following myostatin inhibition, including in disease models of Becker (BMD) and Duchenne muscular dystrophy (DMD) [31,46,47], dysferlinopathy [48], limb-girdle muscular dystrophy type 2A (LGMD2A) [49], calpainopathy [50], and SMA [29,51–54].”
BackgroundEndesfelder, S., Kliche, A., Lochmüller, H., von Moers, A., & Speer, A. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0607-3 · Cited by 8
“In the case of myostatin it has been that its inhibition in vivo by antibodies results in an increase in muscle mass and strength in the mdx mouse [30].”
BackgroundBobbili, N., Kim, Y. S., Dunn, M. A., Yang, J., & Ong, A. (2008) · Food and Agricultural Immunology · doi:10.1080/09540100801956596 · Cited by 10
“…of muscle fibre (Whittemore et al., 2003), and in dystrophic mice the administration of anti-myostatin antibody ameliorated muscular dystrophic conditions as evidenced by an increase in body mass and cross-sectional areas of whole muscle bundles and single fibres (Bogdanovich et al., 2002).”
BackgroundLimback, K. A., Jacobus, W. D., Wiggins-McDaniel, A., Newman, R., & White, R. A. (2022) · Biotechnology Journal International · doi:10.9734/bji/2022/v26i6662 · Cited by 8
Myostatin (GDF-8) as a therapeutic target for the prevention of osteoporotic fractures
Hamrick, M. W. (2010) · IBMS BoneKEy · doi:10.1138/20100423 · Cited by 8
“dystrophy (44), and a humanized myostatin antibody (MYO-029) was shown to be safe and associated with a moderate trend toward increased muscle size in a phase I/II human trial (45).”
BackgroundTherapeutic potential of orphan drugs for the rare skeletal muscle diseases
Swiderski, K., & Lynch, G. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1085858 · Cited by 7
Miao, Y., Soudy, F. A., Xu, Z., Liao, M., Zhao, S., & Li, X. (2017) · BioMed Research International · doi:10.1155/2017/7132941 · Cited by 7
Kim, J. H., Kim, J. H., Sutikno, L. A., Lee, S. B., Jin, D., Hong, Y., Kim, Y. S., & Jin, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215298 · Cited by 8
Sung, D. K., Kim, H., Park, S. E., Lee, J., Kim, J.-A., Park, Y.-C., Jeon, H. B., Chang, J. W., & Lee, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169059 · Cited by 7
“The first preclinical trial of myostatin blockade to treat the DMD in a mouse model (mdx mouse) was performed using a monoclonal antibody against myostatin [19].”
BackgroundMethodGene therapy with anabolic growth factors to prevent muscle atrophy
Schakman, O., & Thissen, J. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000222101.21385.a6 · Cited by 10
Myostatin Blockade: A New Way to Enhance Skeletal Muscle Repair in Old Age?
Yablonka‐Reuveni, Z. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300248 · Cited by 7
Molecular Therapies for Muscular Dystrophies
Lin, A. Y., & Wang, L. H. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0509-2 · Cited by 7
Kim, J. H., Kim, J., Jang, J., Jang, J., Jin, D., Kim, Y., & Jin, H. (2021) · Molecules · doi:10.3390/molecules26092676 · Cited by 10
AAV-dependent targeting of myostatin function: Follistatin strikes back at muscular dystrophy
Colussi, C., Gaetano, C., & Capogrossi, M. C. (2008) · Gene Therapy · doi:10.1038/gt.2008.95 · Cited by 7
Carlsson, M., Frank, E., Màrmol, J. M., Ali, M. S., Raun, S. H., Battey, E., Andersen, N. R., Irazoki, A., Lund, C., Henríquez‐Olguín, C., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102261 · Cited by 8
“Emerging targets to improve both muscle function and glucose homeostasis are the transforming growth factor-β (TGF-β ) family ligands, such as activin A and myostatin [7,8].”
Satkunskienė, D., Ratkevičius, A., Kamandulis, S., & Venckūnas, T. (2018) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2018-0369 · Cited by 7
Diel, P. R., Schiffer, T., Geisler, S., Hertrampf, T., Mosler, S., Schulz, S., Wintgens, F., & Adler, M. (2010) · The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego · doi:10.1210/endo-meetings.2010.part1.p1.p1-45 · Cited by 6
Androgen action on myogenesis throughout the lifespan; comparison with neurogenesis
Barsky, S. T., & Monks, D. A. (2023) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2023.101101 · Cited by 6
Yan-Kun, L. O. U., Luo, J., Dai, R., & Li, N. (2010) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2009.00486 · Cited by 8
Postnatal Hyperplasic Effects of ActRIIB Blockade in a Severely Dystrophic Muscle
Nielsen, C., Potter, R. M., Borowy, C. S., Jacinto, K., Kumar, R., & Carlson, C. G. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25694 · Cited by 8
“…dystrophic muscles, such as the mdx limb musculature, would exhibit a slower accumulation of myonuclei and FCSs and a response to myostatin blockade characterized by some degree of fiber hypertrophy (Bogdanovich et al., 2002; Whittemore et al., 2003; Qiao et al., 2008; Pistilli et al., 2011).”
BackgroundResultGorji, A. E., Ostaszewski, P., Urbańska, K., & Sadkowski, T. (2023) · Biomedicines · doi:10.3390/biomedicines11082329 · Cited by 6
Muscle-specific transgenic expression of porcine myostatin propeptide enhances muscle growth in mice
Wang, K., Li, Z., Li, Y., Zeng, J., Chang, H., Yang, J., Liu, D., & Wu, Z. (2013) · Transgenic Research · doi:10.1007/s11248-013-9709-4 · Cited by 8
“2003) or mice with muscular dystrophy (Bogdanovich et al. 2002).”
BackgroundTgf-β Signaling In Duchenne Muscular Dystrophy
Kemaladewi, D. U., Hoen, P. A. C. ’., ten Dijke, P., van Ommen, G. J., & Hoogaars, W. M. H. (2012) · Future Neurology · doi:10.2217/fnl.12.3 · Cited by 6
Carbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice
Wu, M. P., & Gussoni, E. (2010) · Muscle & Nerve · doi:10.1002/mus.21785 · Cited by 6
“and a decrease in the levels of serum CK.(42) To test whether C-EPO administration led to such changes, serum CK levels were assayed (Fig.”
InfluentialRamalho, T. C., de Castro, A. A., Tavares, T. S., Silva, M. D. C., Silva, D. R., Cesar, P. H., Santos, L. D. A., da Cunha, E. F. F., Nepovimová, E., & Kuča, K. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.06.011 · Cited by 6
“Myostatin, which takes part of the TGF-β superfamily, is a non-positive regulator of muscle growth (Bogdanovich et al., 2002).”
The therapeutic potential of agents that inactivate myostatin
Bishop, A., Kambadur, R., & Sharma, M. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.9.1099 · Cited by 8
“In addition, muscle damage was less evident by histology and there was a significant decrease in serum CK concentrations in myostatin antibodytreated mice [16].”
BackgroundUpdate on therapies for sarcopenia: novel approaches for age-related muscle wasting and weakness
Lynch, G. S. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.9.1329 · Cited by 7
Treatment and Management of Muscular Dystrophies
Escolar, D. M., O'Carroll, P., & Leshner, R. T. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0372-6.00019-0 · Cited by 9
Influence of hyperthyroid conditions on gene expression in extraocular muscles of rats
Postler, T. S., Budak, M. T., Khurana, T. S., & Rubinstein, N. A. (2009) · Physiological Genomics · doi:10.1152/physiolgenomics.00023.2009 · Cited by 5
“Because of its pivotal role in muscle regeneration and growth (6, 26, 27, 48), special interest was taken in the changes in gene expression of myostatin.”
BackgroundSelf-citationNovel Targets and Approaches to Treating Skeletal Muscle Disease
McNally, E. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381510-1.00081-8 · Cited by 5
Saitoh, M., Takayama, K., Roppongi, Y., Shimada, T., Taguchi, A., Taniguchi, A., & Hayashi, Y. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128163 · Cited by 5
La myostatine : un régulateur négatif de la masse musculaire chez les vertébrés
Chelh, I., Rodríguez, J., Bonnieu, A., Cassar‐Malek, I., Cottin, P., Gabillard, J., Leibovitch, S. A., Sassi, A. H., Seiliez, I., & Picard, B. B. (2009) · INRAE Productions Animales · doi:10.20870/productions-animales.2009.22.5.3364 · Cited by 9
Inactivation of myostatin by photo-oxygenation using catalyst-functionalized peptides
Okamoto, H., Taniguchi, A., Usami, S., Taguchi, A., Takayama, K., & Hayashi, Y. (2019) · Chemical Communications · doi:10.1039/c9cc04368c · Cited by 6
Regenerative Rehabilitation for Duchenne Muscular Dystrophy
Swiderski, K., Hardee, J. P., & Lynch, G. S. (2022) · Physiology in health and disease · doi:10.1007/978-3-030-95884-8_4 · Cited by 5
Papel de la miostatina en la afectación muscular asociada a las enfermedades crónicas
Zamora, E., Galán, A., & Simó, R. (2008) · Medicina Clínica · doi:10.1157/13128019 · Cited by 7
Mechanism of satellite cell regulation by myokines
Furuichi, Y., & FUJII, N. L. (2017) · The Journal of Physical Fitness and Sports Medicine · doi:10.7600/jpfsm.6.311 · Cited by 5
Endocrine therapies for sarcopenia in older men
Solomon, A., & Bouloux, P. M. (2006) · British Journal of Hospital Medicine · doi:10.12968/hmed.2006.67.9.22000 · Cited by 7
New Strategies to Fight against Sarcopenia at Old Age
Meynial‐Denis, D., Guérin, O., Schneider, S. M., Volkert, D., & Sieber, C. C. (2012) · Journal of Aging Research · doi:10.1155/2012/676042 · Cited by 7
Maternal immunization against myostatin suppresses post-hatch chicken growth
Mishra, R., Jha, R., Mishra, B., & Kim, Y. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275753 · Cited by 4
Molecular basis of muscle hypertrophy and atrophy: Potential therapy for muscular dystrophy
Ito, N., Miyagoe‐Suzuki, Y., & Takeda, S. (2013) · The Journal of Physical Fitness and Sports Medicine · doi:10.7600/jpfsm.2.179 · Cited by 4
Grafting of a Single Donor Myofibre Promotes Hypertrophy in Dystrophic Mouse Muscle
Boldrin, L., & Morgan, J. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054599 · Cited by 5
“muscle growth [24–26].”
Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy
Chiappalupi, S., Salvadori, L., Luca, G., Riuzzi, F., Calafiore, R., Donato, R., & Sorci, G. (2017) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk2040047 · Cited by 4
“Dystrophic mice lacking myostatin or treated with an anti-myostatin blocking antibody showed increment of muscle mass and muscle strength, together with reduced fibrosis [61,62].”
BackgroundLu‐Nguyen, N., Dickson, G., & Malerba, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8651-4_21 · Cited by 4
Geneand cell-based therapy of muscle system hereditary disorders: state-of-art
Deev, R. V., Мавликеев, М. О., Bozo, I. Y., Pulin, A. A., & Eremin, I. I. (2014) · Genes and Cells · doi:10.23868/gc120368 · Cited by 5
Okamoto, H., Taniguchi, A., Usami, S., Katsuyama, M., Konno, S., Taguchi, A., Takayama, K., & Hayashi, Y. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02042g · Cited by 5
Dudley, R., Comtois, A. S., St‐Pierre, D. H., & Danialou, G. (2021) · FASEB BioAdvances · doi:10.1096/fba.2020-00104 · Cited by 6
Proposal for the binding mode of the 23-mer inhibitory peptide to myostatin
Asari, T., Ikeyama, H., Taguchi, A., Taniguchi, A., Hayashi, Y., & Takayama, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116181 · Cited by 4
Kim, Y. S., Lim, J.-M., Shin, J. S., Kim, H. J., Park, K., & Oh, T. W. (2022) · Molecular & Cellular Toxicology · doi:10.1007/s13273-022-00245-x · Cited by 4
“Previous studies have consistently demonstrated elevated levels of CK in patients with muscular dystrophy and mdx mice, which are known to cause muscle loss (Bogdanovich et al. 2002).”
ResultCarlson, C. G. (2022) · Muscles · doi:10.3390/muscles1010008 · Cited by 6
Regenerative Rehabilitation in Sarcopenia, Dynapenia, and Frailty
Baumann, C. W., Clark, B. C., Phillips, B. E., Szewczyk, N. J., & Consitt, L. A. (2022) · Physiology in health and disease · doi:10.1007/978-3-030-95884-8_5 · Cited by 4
Basic and translational research: from molecule, to mouse, to man
Adams, V., Möbius‐Winkler, S., & Schuler, G. C. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000359236.67432.18 · Cited by 4
Duchenne Muscular Dystrophy: An Update, Part I
Palmieri, B., & Sblendorio, V. T. (2006) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0b013e31802b4785 · Cited by 4
Expression of mdr1 is required for efficient long term regeneration of dystrophic muscle
Israeli, D., Ziaei, S., Gjata, B., Benchaouir, R., Rameau, P., Marais, T., Fukada, S., Segawa, M., Yamamoto, H., Gonin, P., et al. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.02.036 · Cited by 4
Peyronie's Disease: Current Medical Treatment and Future Perspectives
Ryu, J., & Suh, J. (2009) · Korean journal of urology · doi:10.4111/kju.2009.50.6.527 · Cited by 4
Endocrine therapies for sarcopenia in older men
Solomon, A., & Bouloux, P. M. (2006) · British Journal of Hospital Medicine · doi:10.12968/hmed.2006.67.sup9.22000 · Cited by 4
Satellite cell depletion in early adulthood attenuates muscular dystrophy pathogenesisPreprint
Boyer, J. G., Han, S., Prasad, V., Khalil, H., Vagnozzi, R. J., & Molkentin, J. D. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/857433 · Cited by 5
“Specifically, inhibition of myostatin, a negative regulator of muscle mass, led to strength increases in mdx mice and better performance (Bogdanovich et al., 2002; Jin et al., 2019; St Andre et al., 2017).”
BackgroundCachexia in pancreatic cancer – Mechanisms and potential intervention
Bartosch-Härlid, A., & Andersson, R. E. (2009) · e-SPEN the European e-Journal of Clinical Nutrition and Metabolism · doi:10.1016/j.eclnm.2009.10.002 · Cited by 3
Ramírez-Andoney, V., Gayosso-Vázquez, A., Ríos, J. P. P., Buchelli, J. E. V., & Morales, R. A. A. (2019) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-019-0092-8 · Cited by 3
Gene therapy approaches to the duchenne muscular dystrophy theatment
Zaynitdinova, M. I., Smirnikhina, S. A., Lavrov, A. V., Eremin, I. I., & Pulin, A. A. (2019) · Genes and Cells · doi:10.23868/201912026 · Cited by 4
Shalash, R., Levi‐Ferber, M., Cohen, C., Dori, A., Brodie, C., & Henis‐Korenblit, S. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050412 · Cited by 3
“Additional treatments are being developed for DMD (Duan et al., 2021), including anti-inflammatory and anti-fibrotic agents (Bushby et al., 2010; Heier et al., 2013; Huebner et al., 2008; Levi et al., 2015) and agents increasing muscle regeneration (Bogdanovich et al., 2002).”
Drug Discovery Approaches for Rare Neuromuscular Diseases
Wynne, G. M., & Russell, A. J. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00257 · Cited by 3
Follistatin Protein Enhances Satellite Cell Counts in Reinnervated Muscle
Feger, M. A., Isaacs, J. E., Mallu, S., Yager, D., Shall, M. S., Patel, G., Protzuk, O. A., & Bokkisam, A. S. (2022) · Journal of Brachial Plexus and Peripheral Nerve Injury · doi:10.1055/s-0042-1748535 · Cited by 3
Donati, F., Biasini, G. M., de la Torre, X., & Botrè, F. (2023) · Biology of Sport · doi:10.5114/biolsport.2024.132982 · Cited by 3
“It was also shown that in vivo injections of MYO binding antibodies can be effective in neutralizing MYO as a therapeutic strategy to treat dystrophies [19].”
BackgroundTakemasa, T., Yakushiji, N., Kikuchi, D. M., Deocaris, C. C., Widodo, N., Machida, M., & Kiyosawa, H. (2012) · Europe PMC (PubMed Central) · Cited by 6
Abnormal Muscle Pathology and Physiology
Bogdanovich, S., Gardner, B. B., & McNally, E. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800040-3.00004-2 · Cited by 3
Self-citationNovel Intriguing Strategies Attenuating to Sarcopenia
Sakuma, K., & Yamaguchi, A. (2016) · Apple Academic Press eBooks · doi:10.1201/9781315364971-12 · Cited by 3
(2009) · Molecular Therapy · doi:10.1016/s1525-0016(16)38744-5 · Cited by 3
Description of muscle disease – general aspects
Karpati, G. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511674747.012 · Cited by 3
Could gene therapy be the future for muscular dystrophy?
Haidet, A. M., Mendell, J. R., & Kaspar, B. K. (2010) · Therapy · doi:10.2217/thy.10.14 · Cited by 4
“A wide variety of both pharmacological and gene therapy approaches have been developed to inhibit myostatin [28– 30].”
BackgroundOn the path to a Duchenne muscular dystrophy therapy.
Fallon, J. R. (2013) · PubMed · Cited by 3
Cardiac Complications of Neuromuscular Disorders
Spurney, C. F. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0372-6.00003-7 · Cited by 3
Davies, K. E., & Khurana, T. S. (2007) · Nature Medicine · doi:10.1038/nm0507-538 · Cited by 3
Self-citationFunctional Enhancement of Skeletal Muscle by Gene Transfer
Gregorevic, P., & Chamberlain, J. S. (2005) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2005.08.011 · Cited by 3
“In an attempt to regulate myostatin activity negatively, groups have sought to reduce translation of myostatin transcripts via expression of short interfering RNA sequences [57], reduce circulating protein levels via infusion of myostatin-specific antibodies [58,59], and inhibit proteolytic activation of myostatin by…”
BackgroundAslam, M. R., Bilal, M., Nawaz, A., Kado, T., Abe, S., Phuong, N. Q., Memoona, M., Khalid, S., Anh, L. D., Nishimura, A., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01393-1 · Cited by 3
Cadena, S. M., Bogdanovich, S., Khurana, T. S., Pullen, A. E., Pearsall, R. S., Curran, E., Faucette, R., Lane, J., Seehra, J. S., Lachey, J. L., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342666 · Cited by 2
“Indeed, although myostatin specific treatments have been shown to be efficacious in a mouse model of muscular dystrophy [18,24,27], selective antagonism of myostatin has failed to show meaningful clinical benefit in patients with muscular dystrophies [29–31].”
InfluentialSelf-citationFrom Basic Research to Clinical Trials: Preclinical Trial Evaluation in Mouse Models
Bogdanovich, S., & Emídio, E. C. P. (2012) · InTech eBooks · doi:10.5772/30920 · Cited by 2
Self-citationMangrulkar, S. V., Chaple, D., Korewar, S., Mazumdar, P., & Twinkle, C. (2020) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2020.017 · Cited by 2
Brandsema, J. F., & Darras, B. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00024-2 · Cited by 2
Malerba, A., Harish, P., & Popplewell, L. J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2772-3_30 · Cited by 2
Impoverished Conceptions of Gene Causation and Therapy in Developmental Neurology
Pascual, J. M., Jakkamsetti, V., Málaga, I., & Noble, D. (2023) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2023.07.017 · Cited by 2
Lam, P. M. W., Zygmunt, D. A., Ashbrook, A., Bennett, M., Vetter, T. A., & Martin, P. T. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.028 · Cited by 2
Cardiac involvement in the dystrophinopathies
Russell, M. W. W., Townsend, D., & Metzger, J. M. (2008) · Journal of Pediatric Rehabilitation Medicine · doi:10.3233/prm-2008-00037 · Cited by 2
“Several other therapies, including myostatin inhibition [9] which encourages skeletal muscle growth/ regeneration, utrophin upregulation [64] which com-220 pensates for loss of functional dystrophin and stem cell infusion [80] which provides replacement cells formus-cle repair and regeneration, are…”
Adaptation to resistance training
Wackerhage, H., & Atherton, P. J. (2006) · Elsevier eBooks · doi:10.1016/b978-0-443-10077-2.50009-2 · Cited by 4
Association Between MSTN Gene Polymorphism and Growth Traits in Landrace Pigs
Cho, I. C. (2005) · Journal of Animal Science and Technology · doi:10.5187/jast.2005.47.2.159 · Cited by 2
La miostatina: un regulador autocrino/paracrino del desarrollo muscular
Arce, V. M., Carneiro, I., Fernández‐Nocelo, S., & Devesa, J. (2005) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(05)71031-7 · Cited by 3
“Una de las opcio-nes, utilizada con éxito en ratones, es la administra-ción sistémica de anticuerpos antimiostatina 29,55 .”
Developmental Role for Myostatin in Regulating Myogenesis
Otto, A., Matsakas, A., & Patel, K. (2010) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152210793663766 · Cited by 2
“Moreover, it has also been suggested that adult skeletal muscle repair is accelerated in the Myostatin, and that the mdx mouse phenotype, a model for muscular dystrophy, shows an alleviation of symptoms following Myostatin knockdown or genetic ablation [44, 45].”
BackgroundYahyaei, B., Nouri, M., & Matmir, H. (2018) · Revista de Fomento Social · doi:10.29252/jorjanibiomedj.6.1.12 · Cited by 2
“also a significant effect on elevating testosterone levels, luteinizing hormone (LH) and follicular stimulatory hormones (FSH) in men (14-15).”
BackgroundDuchenne Muscular Dystrophy: An Update, Part II
Palmieri, B., & Sblendorio, V. T. (2007) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0b013e31802b4b4a · Cited by 2
“kinase levels, suggesting that some degree of functional improvements had occurred.(57) Van Erp et al(58) testedwhether the TGF-b antagonist, pirfenidone, could reduce cardiac fibrosis.”
BackgroundFacioscapulohumeral Muscular Dystrophy
Himeda, C. L., & Emerson, C. P. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381510-1.00069-7 · Cited by 2
The effect of taurine on dystrophic muscle tissue function
Horvath, D. (2011) · Victoria University Research Repository (Victoria University) · Cited by 2
Patel, K., & Muntoni, F. (2004) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.03.001 · Cited by 2
“Indeed mdx mice lacking myostatin are stronger and more muscular than their mdx counterparts [5].”
BackgroundSkeletal Muscle Specific IRES Activity of Utrophin A Is Enhanced by Eef1a2
Coriati, A. (2011) · Library and Archives Canada (Government of Canada) · doi:10.20381/ruor-4496 · Cited by 2
“The improved regenerative capacity, as well as increased strength and growth of dystrophic muscles in mdx mice, could be achieved by blocking endogenous myostatin expression using anti-myostatin antibodies (Bogdanovich et al., 2002).”
BackgroundTherapeutics in Duchenne muscular dystrophy
Strober, J. B. (2006) · Neurotherapeutics · doi:10.1007/bf03207052 · Cited by 2
Signaling Pathways Controlling Muscle Fiber Size and Type In Response To Nerve Activity
Schiaffino, S., Sandri, M., & Murgia, M. (2007) · Springer eBooks · doi:10.1007/1-4020-5177-8_4 · Cited by 2
Jakkamsetti, V., Ma, Q., Angulo, G., Scudder, W., Beutler, B., & Pascual, J. M. (2024) · The Journal of Physiology · doi:10.1113/jp285505 · Cited by 1
“Disorders as different as muscular dystrophy and spinal muscular atrophy benefit from myostatin blockade in mice (Bogdanovich et al., 2002; Long et al., 2019), suggesting that genetic or pharmacological modulation outside the primary disease locus can mitigate motor impairment.”
BackgroundLeite, F. D. S., Lambert, M. R., Zhang, T., Conner, J. R., Paulo, J. A., Oliveira, S. F., Thakurta, S. G., Bowles, J., Gussoni, E., Gygi, S. P., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2506437122 · Cited by 2
“Additionally, a myostatin knockout mouse model also shows a higher proportion of type IIB fibers ( 49 ), and myostatin blockade with antibodies in the mdx mouse showed improved muscle function, stronger absolute force, and no difference in eccentric force resistance to eccentric contractions ( 11 ).”
Rodgers, B. D., & Ward, C. W. (2025) · Gene Therapy · doi:10.1038/s41434-025-00583-0 · Cited by 2
Lei, C., Jiang, H., Yang, X., Ding, S., Yu, Y., Zhang, Z., Wang, L., Gao, C., Lü, A., Qin, L., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093836 · Cited by 1
“The suppression of regeneration and the acceleration of atrophy both contribute to the imbalance between muscle degradation and regeneration, which is a characteristic feature of DMD pathology [75].”
Metadata
- Authors
- Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S.
- Affiliations
- University of Pennsylvania (US)
- Pfizer (United States) (US)
- Corresponding author
- Khurana, Tejvir S.
- Venue
- Nature
- Published
- 2002-11
- Volume
- 420
- Issue
- 6914
- Pages
- 418-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2083700023
- Semantic Scholar
- 590fb54cd1f2d89d44f4e1ad999be802dc756277
- Cited by
- 831
- References
- 31
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 19 · 2023: 15 · 2022: 21 · 2021: 20 · 2020: 23 · 2019: 32 · 2018: 23 · 2017: 34 · 2016: 28 · 2015: 43 · 2014: 34 · 2013: 38 · 2012: 48
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- myostatin, Duchenne muscular dystrophy, mdx mice, muscle atrophy, blocking antibodies, muscle mass, muscle strength, muscle degeneration, creatine kinase, TGF-beta superfamily, skeletal muscle growth
- MeSH terms
- Animals, Antibodies, Body Weight, Creatine Kinase, Male, Muscular Dystrophy, Animal, Organ Size, Transforming Growth Factor beta, Mice, Inbred mdx, Muscle, Skeletal, Muscle Fibers, Skeletal, Muscular Dystrophy, Duchenne, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.